ACE-I vs angiotensin II receptor antagonists: Prevention of renal injury in chronic rat models

Journal of Human Hypertension

Volumn 13, Issue , 1999, Pages S51-S56

  Taal, M W ^a   Brenner, B M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin type I receptor antagonist; Angiotensin converting enzyme inhibitor; Bradykinin; Chronic renal disease; Glomerulosclerosis

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY DILATATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; GLOMERULOSCLEROSIS; KIDNEY INJURY; NONHUMAN; PATHOGENESIS; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BRADYKININ; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENALAPRIL; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HYPERTENSION, RENAL; PEPTIDYL-DIPEPTIDASE A; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 0032939219     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000742     Document Type: Article

References (41)

1. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. 1985; 76: 612-619.
2. Zatz R et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
3. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456 - 1462.
5. Ravid M Long-term stabilizing effect of angioten- sin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
6. Maschio G Effect of angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Con- verting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Eng J Med 1996; 334: 939- 945.
7. Navar GN, Rosivall L. Contribution of the renin-angiot- ensin system to the control of intrarenal hemodynamics. Kidney Int 1984; 25: 857-868.
8. Miller PL, Rennke H, Meyer TW. Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol (Renal Fluid Electrolyte Physiol) 1991; 261: F459-F465.
9. Lapinski R Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996; 7: 653-660.
10. Fujiwara Y Angiotensin II stimulates mesangial cell growth through phosphoinositide cascade. Kidney Int 1989; 35: 172 (Abstract).
11. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
12. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angioten- sin-converting enzyme. J Cardiovasc Pharmacol 1995; 26: 233-240.
13. Mombouli J-V, Vanhoutte PM. Heterogeneity of endo- thelium-dependent vasodilator effects of angiotensin- converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992; 20 (Suppl 9): S74-S83.
14. Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circulation Res 1993; 72: 1202-1210.
15. Liu Y-H Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest1997; 99: 1926-1935.
16. Hutchison FN, Cui X, Webster SK. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995; 6: 1216-1222.
17. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-550.
18. Carretero O, Polomski C, Scicli A. Role of kinins and nitric oxide in the renal protective of ACE-I in the subtotal nephrectomy model. Hypertension (Dallas) 1993; 22: 415 (Abstract).
19. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449.
20. Tian B Intrarenal angiotensin II generation is per- served in mice lacking the angiotensin converting enzyme gene. J Invest Med 1997; 45: 58A (Abstract).
21. Nishimura H Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int1996; 49 (Suppl 55): S18-S23.
22. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens 1994; 12 (Suppl 9): S17-S22.
23. Lo M, Liu K-L, Lantelme P, Sassard J. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995; 95: 1394-1397.
24. Goto M Angiotensin II AT2 receptor mediates antiproliferative and apoptotic action in cultured rat mesangial cells. J Am Soc Nephrol 1997; 8: 438 (Abstract).
25. Nakajima M The angiotensin II type 2 receptor antagonizes the growth effects of the ATI receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci 1995; 92: 10663-10667.
26. Ichiki T Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377: 748-750.
27. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766- 771.
28. Kakinuma Y Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46-55.
29. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993; 267: 657-663.
30. Brooks DP SB 203220: a novel angiotensin II receptor antagonist and renoprotective agent. J Pharmacol Exp Ther 1995; 274: 1222-1227.
31. Okada H Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995; 26: 564- 569.
32. Noda M Effects of candesartan cilexetil (TCV- 116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997; 52 (Suppl 63): S136-S139.
33. Ots M Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9: 224-230.
34. Ziai F The angiotensin receptor antagonist, irbes- artan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996; 50 (Suppl 57): S132- S136.
35. Imamura A Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int 1995: 47: 1394-1402.
36. Anderson A, Tolbert E, Esparza A, Dworkin L. Effects of an ACE inhibitor versus an All antagonist on hemodynamics, growth, and injury in spontaneously hypertensive rats. J Am Soc Nephrol 1996; 7: 1849 (Abstract).
37. Zoja C The renoprotective properties of angioten- sin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 1997; 29: 254-264.
38. Remuzzi A Comparison of the effects of angioten- sin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol1996; 4: 19-25.
39. Sakemi T, Baba N. Effects of angiotensin II receptor antagonist on the progression of renal failure in hyper- lipidemic Imai rats. Nephron 1993; 65: 426-432.
40. Benediktsson H, Chea R, Davidoff A, Paul LC. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Transplantation 1996; 62: 1634- 1642.
41. Mackenzie HS, Troy JL, Rennke HG, Brenner BM. TCV116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 1994; 12 (Suppl 9): S11-S16.